10. K. Mulsow, et al. "Quantifizierung des Mistellektins I aus Mistelextrakt-Fertigarzneimitteln [Quantification of mistletoe lectin I from mistletoe extract finished medicinal products]," *ZPT—Zeitschrift für Phytotherapie*, 2017; 38:148-151.
11. Original data set included a Helixor Pini batch with a higher reading of 2,100 ng/mL and 2,200 ng/mL of A-Chain and A-B Chain mistletoe lectins, respectively.
12. M. Girke, *Internal Medicine: Foundations and therapeutic concepts of Anthroposophic Medicine* (Berlin: Salumed-Verlag, 2016), chap. 14.3.5.6.
13. Author Note: This section is composed of general anthroposophic recommendations accumulated through decades of clinical practice, as well as from *Vademecum of Anthroposophic Medicines* (Association of Anthroposophic Medicine in Germany [GAAD], 2019), pp. 42–110. J. Wilkens and G. Böhm, *Mistletoe Therapy for Cancer*, Op. cit.
14. *Vademecum of Anthroposophic Medicines*. Association of Anthroposophic Medicine in Germany (GAAD), 2019, (chap. 5).
15. Ibid., chap. 9.
16. M. Girke, *Internal Medicine: Foundations and therapeutic concepts of Anthroposophic Medicine* (Berlin: Salumed-Verlag, 2016), chap. 14.3.5.6.
17. *Vademecum of Anthroposophic Medicines* (Association of Anthroposophic Medicine in Germany [GAAD], 2019), chap. 5.
18. R. Steiner, *Introducing Anthroposophical Medicine* (CW 312). Op. cit.
19. J. U. Umeafoekwe, et al. "Pulmonary effects of grain-dust observed in feedmill workers," Proceedings of the 6th National Conference of the Society for Occupational Safety and Environmental Health (SOSEH). Nov. 3–6, 2010. Princess Alexandra Auditorium, University of Nigeria, Nsukka, Enugu State, Nigeria.
20. J. Wilkens and G. Böhm, *Mistletoe Therapy for Cancer*, Op. cit., p. 53.
21. T. M. Dudenkov, et al. "SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: Genome-wide association studies of the estrone pathway," *Breast Cancer Research and Treatment*, vol. 164,1 (2017): 189–99. doi:10.1007/s10549-017-4243-3.
22. C. A. Thomson, et al. "Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: Evidence from experimental and human studies," *Nutrition Reviews*, vol. 74,7 (2016): 432–43. doi:10.1093/nutrit/nuw010.
23. J. Wilkens and G. Böhm. *Mistletoe Therapy for Cancer*, Op. cit., p. 75.

Chapter 5

1. N. Winters and J. H. Higgins Kelley. *The Metabolic Approach to Cancer Care: Integrating Deep Nutrition, the Ketogenic Diet, and Nontoxic Bio-individualized Therapies*, Hartford, VT: Chelsea Green, 2017.
2. H. A. Coller. "Is cancer a metabolic disease?" *The American Journal of Pathology*, vol. 184,1 (2014): 4-17. doi:10.1016/j.ajpath.2013.07.035.
3. G. P. Dunn, et al. "The immunobiology of cancer immunosurveillance and immunoediting," *Immunity*, vol. 21, no. 2, 2004, pp. 137–48.

4. F. M. Burnet. "The concept of immunological surveillance," *Prog. Exp. Tumor Res.*, 1970;13:1–27.
5. D. D. Chaplin. "Overview of the immune response," *Journal of Allergy and Clinical Immunology,* vol. 125,2 Suppl 2 (2010): S3–23. doi:10.1016/j.jaci.2009.12.980.
6. H. Gonzalez, et al. "Roles of the immune system in cancer: From tumor initiation to metastatic progression," *Genes and Development,* vol. 32,19–20 (2018): 1267-1284. doi:10.1101/gad.314617.118.
7. A. C. West, et al. "An intact immune system is required for the anticancer activities of histone deacetylase inhibitors," *Cancer Research,* Dec. 15, 2013; 73(24):7265-7276. doi:10.1158/0008-5472.CAN-13-0890.
8. A. A. Shafi and K. E. Knudsen, "Cancer and the circadian clock," *Cancer Res.*, Aug. 1 2019 79 (15) 3806–14. doi:10.1158/0008-5472.CAN-19-0566.
9. Salavaty, Abbas. "Carcinogenic effects of circadian disruption: an epigenetic viewpoint," *Chinese Journal of Cancer,* vol. 34,9 375–83. 8 Aug. 2015, doi:10.1186/s40880-015-0043-5.
10. G. Sulli, et al. "Interplay between circadian clock and cancer: New frontiers for cancer treatment." *Trends in Cancer,* vol. 5,8 (2019): 475–94. doi:10.1016/j.trecan.2019.07.002.
11. J. K. Kiecolt-Glaser and R. Glaser. "Psychoneuroimmunology and health consequences: Data and shared mechanisms," *Psychosomatic Medicine,* vol. 57,3 (1995): 269–74. doi:10.1097/00006842-199505000-00008.
12. R. H. Bonneau, et al. "Twenty years of psychoneuroimmunology and viral infections in brain, behavior, and immunity," *Brain, Behavior, and Immunity,* vol. 21,3 (2007): 273–80. doi:10.1016/j.bbi.2006.10.004.
13. E. Walter and M. Scott. "The life and work of Rudolf Virchow 1821–1902: Cell theory, thrombosis and the sausage duel," *Journal of the Intensive Care Society,* vol. 18,3 (2017): 234–35. doi:10.1177/1751143716663967.
14. M. J. Bissell. "Architecture is the message: The role of extracellular matrix and 3-d structure in tissue-specific gene expression and breast cancer," *The Pezcoller Foundation Journal: News from the Pezcoller Foundation World,* vol. 16,29 (2007): 2–17.
15. C. M. Nelson, et al. "Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer," *Annual Review of Cell and Developmental Biology,* vol. 22 (2006): 287–309. doi:10.1146/annurev.cellbio.22.010305.104315.
16. M. Song, et al. "Neutrophil-to-lymphocyte ratio and mortality in the United States general population," *Scientific Reports,* vol. 11,1 464. 11 Jan. 2021, doi:10.1038/s41598-020-79431-7.
17. M. A. Cupp, et al. "Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies," *BMC Medicine,* vol. 18,1 360. 20 Nov. 2020, doi:10.1186/s12916-020-01817-1.
18. Y. Pascual-González, et al. "Defining the role of neutrophil-to-lymphocyte ratio in COPD: A systematic literature review." *International Journal of Chronic Obstructive Pulmonary Disease,* vol. 13 3651–62. Nov. 5, 2018, doi:10.2147/COPD.S178068.

19. M. A. Cupp, et al. "Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies," *BMC Medicine,* 18, 360 (2020). https://doi.org/10.1186/s12916-020-01817-1.
20. J. Fest, et al. "The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam study." *European Journal of Epidemiology,* vol. 34,5 (2019): 463–70. doi:10.1007/s10654-018-0472-y.
21. M. U. Mushtaq, et al. "Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes," *Journal of Clinical Oncology,* 2016 34:15; suppl, 7062.
22. S. Mallappa, et al. "Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer." *Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland,* vol. 15,3 (2013): 323–28. doi:10.1111/codi.12008.
23. G. Moon, et al. "Prediction of late recurrence in patients with breast cancer: Elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence," *Breast Cancer* (Tokyo), vol. 27,1 (2020): 54–61. doi:10.1007/s12282-019-00994-z.
24. M. Gago-Dominguez, et al. "Neutrophil to lymphocyte ratio and breast cancer risk: Analysis by subtype and potential interactions," *Scientific Reports,* 10, 13203 (2020). https://doi.org/10.1038/s41598-020-70077-z.
25. M. U. Mushtaq, et al. "Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes," *Journal of Clinical Oncology,* 2016 34:15; suppl, 7062.
26. G. Leone, et al. "The incidence of secondary leukemias," *Haematologica,* 1999 Oct;84(10):937–45. PMID: 10509043.
27. B. Zhang, et al. "How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy," *Cancer Biology and Therapy,* vol. 17,2 (2016): 125–28. doi:10.1080/15384047.2016.1139233.
28. Author Note: This effect on neutrophil and leukocyte numbers is primarily a clinically observed effect, but a fine discussion of this may also be seen here: C. Saha. "Unravelling the therapeutic intervention of inflammation and cancer by Viscum album: Understanding its anti-inflammatory and immunostimulatory properties," *Biotechnology,* Université de Technologie de Compiègne, 2015. English. NNT: 2015COMP2210. HAL ID tel-01214953.
29. Author Note: IL-6 is a marker of general inflammation that does not negate the use of VAE. In fact, VAE lowers that value. It is IL-8, however, that may negate our ability to use VAE, until we get IL-8 under control.
30. M. F. Sanmamed, et al. "Serum Interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins," *Clin. Cancer Res.,* 20(22) Nov. 15, 2014, 5697–707.
31. R. Huber, et al. "Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: A placebo-controlled randomized study in healthy subjects," *European Journal of Medical Research,* vol. 10,10 (2005): 411–18.

32. J. L. Sylman, et al. "A temporal examination of platelet counts as a predictor of prognosis in lung, prostate, and colon cancer patients." *Scientific Reports,* vol. 8,1 6564. Apr. 26, 2018, doi:10.1038/s41598-018-25019-1.
33. B. Norbaini et al. "Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment." *Cancers,* vol. 10,10 380. 11 Oct. 2018, doi:10.3390/cancers10100380.
34. S. Sen, et al. "Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials." *British Journal of Cancer,* vol. 118,6 (2018): 763-769. doi:10.1038/bjc.2017.480.
35. S. Shrotriya, et al. "C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review." *PloS One,* vol. 10,12 e0143080. Dec. 2015. doi:10.1371/journal.pone.0143080.
36. A. Katano, et al. "The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy," *Sci. Rep.,* 7, 17805 (2017). https://doi.org/10.1038/s41598-017-18233-w.
37. J. J. Hu, et al. "Association between inflammatory biomarker c-reactive protein and radiotherapy-induced early adverse skin reactions in a multiracial/ethnic breast cancer population," *Journal of Clinical Oncology,* 36, no. 24 (Aug. 20, 2018) 2473-2482. DOI: 10.1200/JCO.2017.77.1790.
38. F. A. Mahmoud and N. I. Rivera. The role of C-reactive protein as a prognostic indicator in advanced cancer. *Current Oncology Report,* 4, 250–255 (2002). https://doi.org/10.1007/s11912-002-0023-1.
39. Author Note: CRP has also been examined as a diagnostic tool for cancer risk. For instance: J. Watson, et al. "Predictive value of inflammatory markers for cancer diagnosis in primary care: A prospective cohort study using electronic health records," *British Journal of Cancer,* 120 (2019), 1045–51. https://doi.org/10.1038/s41416-019-0458-x.
40. C. Yadav, et al. "Serum lactate dehydrogenase in non-Hodgkin's lymphoma: A prognostic indicator," *Indian Journal of Clinical Biochemistry,* vol. 31,2 (2016), 240-2. doi:10.1007/s12291-015-0511-3.
41. A. Farhana and S. L. Lappin. *Biochemistry, Lactate Dehydrogenase* (updated 2020 May 17); in StatPearls (online). Treasure Island, FL: StatPearls, 2021. https://www.ncbi.nlm.nih.gov/books/NBK557536/.
42. D. Mishra and D. Banerjee. "Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment," *Cancers,* vol. 11,6 750. 29 May. 2019, doi:10.3390/cancers11060750.
43. Ibid.
44. T. N. Seyfried, et al. "Cancer as a metabolic disease: Implications for novel therapeutics," *Carcinogenesis,* vol. 35,3 (2014): 515–27. doi:10.1093/carcin/bgt480.
45. S. Shrotriya, et al. "C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review," *PloS One,* vol. 10,12 e0143080. 30 Dec. 2015, doi:10.1371/journal.pone.0143080.

46. Author Note: Regarding monitoring vitamin D levels, I routinely screen my patients' 1,25 and 25-OH levels prior to vitamin D supplementation and then watch their serum calcium levels monthly during supplementation to make sure there are no issues with hypercalcemia. I have yet to see D3 toxicity occur. If I see serum calcium rise, then we simply stop the D3 supplementation for a few days (but continue taking K2), then resume D3 at much lower doses. That's all that's needed.
47. A. J. van Ballegooijen, et al. "The Synergistic Interplay between vitamins D and K for bone and cardiovascular health: A narrative review," *International Journal of Endocrinology,* vol. 2017 (2017): 7454376. doi:10.1155/2017/7454376.
48. S. Goddek. "Vitamin D3 and K2 and their potential contribution to reducing the covid-19 mortality rate," *International Journal of Infectious Diseases: Official Publication of the International Society for Infectious Diseases,* vol. 99 (2020): 286-290. doi:10.1016/j.ijid.2020.07.080.
49. N. R. Parva, et al. "Prevalence of vitamin D deficiency and associated risk factors in the US population (2011–2012)," *Cureus,* vol. 10,6 e2741. 5 Jun. 2018, doi:10.7759/cureus.2741.
50. J. Chan, et al. "Serum 25-hydroxyvitamin D status of vegetarians, partial vegetarians, and nonvegetarians: The Adventist health study-2," *The American Journal of Clinical Nutrition,* vol. 89,5 (2009): 1686S-1692S. doi:10.3945/ajcn.2009.26736X.
51. L. Vranić, et al. "Vitamin D deficiency: Consequence or cause of obesity?" *Medicina* (Kaunas, Lithuania), vol. 55,9 541. 28 Aug. 2019, doi:10.3390/medicina55090541.
52. U. Gröber and K. Kisters. "Influence of drugs on vitamin D and calcium metabolism," *Dermato-endocrinology,* vol. 4,2 (2012): 158-66. doi:10.4161/derm.20731.
53. Author Note: 42 percent is the actual number noted in studies. But that is based on "average" findings, showing that 42 percent of the population has D3 levels *under 30.* The vitamin D deficiency percentage is closer to 70 percent when we look at those with levels under 50.
54. N. R. Parva, et al. "Prevalence of vitamin D deficiency and associated risk factors in the US population (2011–2012)," *Cureus,* vol. 10,6 e2741. 5 Jun. 2018, doi:10.7759/cureus.2741.
55. B. Loef, et al. "Immunological effects of shift work in healthcare workers," *Scientific Reports,* vol. 9,1 18220. 3 Dec. 2019, doi:10.1038/s41598-019-54816-5.
56. T. W. Kim et al. "The impact of sleep and circadian disturbance on hormones and metabolism," *Int. Journal of Endocrinology,* 2015;2015:591729. doi: 10.1155/2015/591729. Epub 2015 Mar 11. PMID: 25861266; PMCID: PMC4377487.
57. S. P. Megdal, et al. "Night work and breast cancer risk: A systematic review and meta-analysis," *European Journal of Cancer* (Oxford, UK: 1990), vol. 41,13 (2005): 2023-32. doi:10.1016/j.ejca.2005.05.010.
58. X. Yuan, et al. "Night shift work increases the risks of multiple primary cancers in women: A systematic review and meta-analysis of 61 articles," *Cancer Epidemiol Biomarkers Prev.,* 2018 Jan; 27(1):25-40.

59. E. Pukkala, et al. "Incidence of cancer among Finnish airline cabin attendants, 1967–92." *BMJ* (Clinical Research ed.), vol. 311,7006 (1995): 649–52. doi:10.1136/bmj.311.7006.649.
60. Oct. 2, 2017 Nobel Prize press release: https://www.nobelprize.org/prizes/medicine/2017/press-release/. Accessed Apr. 28, 2021.
61. J. C. Dunlap. "Molecular bases for circadian clocks," *Cell*, Jan. 22, 1999; 96(2):271-90. doi: 10.1016/s0092-8674(00)80566-8. PMID: 9988221.
62. D. Bell-Pedersen, et al. "Circadian rhythms from multiple oscillators: Lessons from diverse organisms," *Natural Reviews: Genetics*, Jul. 2005;6(7):544–56. doi: 10.1038/nrg1633. PMID: 15951747; PMCID: PMC2735866.
63. R. Pryor, et al. "The role of the microbiome in drug response," *Annual Review of Pharmacology and Toxicology*, vol. 60 (2020): 417–35. doi:10.1146/annurev-pharmtox-010919-023612.
64. W. Ma, et al. "Gut microbiota shapes the efficiency of cancer therapy," *Frontiers in Microbiology*, vol. 10 1050. Jun. 25, 2019, doi:10.3389/fmicb.2019.01050.
65. AUTHOR NOTE: Low D3 directly impacts hundreds of epigenetic switches, affecting metabolic function, hormonal regulation, and immune response, as shown in I. S. Fetahu, et al. "Vitamin D and the epigenome," *Front Physiol.*, Apr. 2014 29;5:164. doi: 10.3389/fphys.2014.00164. PMID: 24808866; PMCID: PMC4010791.
66. AUTHOR NOTE: Low D3 levels are also associated with depression and dopamine issues in particular, as shown in I. Anjum, et al. "The role of vitamin D in brain health: A mini-literature review," *Cureus*, Jul. 2018 10;10(7):e2960. doi: 10.7759/cureus.2960. PMID: 30214848. PMCID: PMC6132681.
67. B. S. McEwen. "Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators," *European Journal of Pharmacology*, vol. 583,2-3 (2008): 174–85. doi:10.1016/j.ejphar.2007.11.071.
68. E. K. Adam, et al. "Diurnal cortisol slopes and mental and physical health outcomes: A systematic review and meta-analysis," *Psychoneuroendocrinology*, vol. 83 (2017): 25-41. doi:10.1016/j.psyneuen.2017.05.018.
69. L. Fiorentino and S. Ancoli-Israel. "Sleep dysfunction in patients with cancer," *Current Treatment Options in Neurology*, vol. 9,5 (2007): 337–46.
70. A. S. Prasad. "Zinc in human health: Effect of zinc on immune cells," *Mol. Med.*, May–Jun. 2008; 14(5-6): 353–357.
71. E. Prado de Oliveira and R. C. Burini. "High plasma uric acid concentration: Causes and consequences," *Diabetol. Metab. Syndr.*, 4, 12 (2012). https://doi.org/10.1186/1758-5996-4-12.
72. M. Jung, et al. "Iron as a central player and promising target in cancer progression," *International Journal of Molecular Sciences*, vol. 20,2 273. Jan. 11, 2019, doi:10.3390/ijms20020273.
73. D. Galaris, et al. "Iron homeostasis and oxidative stress: An intimate relationship," *Biochimica et Biophysica Acta (BBA): Molecular Cell*

Research, vol. 1866, no. 12, 2019, 118535, ISSN 0167-4889, https://doi.org/10.1016/j.bbamcr.2019.118535.

74. P. R. Bock, et al. "Targeting inflammation in cancer-related-fatigue: A rationale for mistletoe therapy as supportive care in colorectal cancer patients," *Inflamm. Allergy Drug Targets,* 2014;13(2):105-11. doi: 10.2174/1871528113666140428103332. PMID: 24766319; PMCID: PMC4133960.
75. M. Kröz, et al. "Mistletoe: From basic research to clinical outcomes in cancer and other indications," *Evidence-based Complementary and Alternative Medicine,* vol. 2014, Article ID 987527, 2 pages, 2014. https://doi.org/10.1155/2014/987527.
76. S. C. Segerstrom, et al. "Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry," *Psychological Bulletin,* vol. 130,4 (2004): 601–30. doi:10.1037/0033-2909.130.4.601.
77. Ibid.
78. S. A. Font and K. Maguire-Jack, "Pathways from childhood abuse and other adversities to adult health risks: The role of adult socioeconomic conditions," *Child Abuse and Neglect,* 51, no. 2 (2016): 390–99.
79. L. LeShan, *Cancer as a Turning Point: A Handbook for People with Cancer, Their Families, and Health Professionals,* New York: Plume, 1994.
80. K. Turner, *Radical Remission: Surviving Cancer Against All Odds,* San Francisco: HarperOne, 2015.
81. Y. Balhara. "Diabetes and psychiatric disorders," *Indian Journal of Endocrinology and Metabolism,* vol. 15,4 (2011): 274–83. doi:10.4103/2230-8210.85579.
82. A. Felman. "How does diabetes affect mood and relationships?" *Medical News Today* (medically reviewed by D. Weatherspoon, PhD, RN, CRNa) May 24, 2019; published at https://www.medicalnewstoday.com/articles/317458. Retrieved Apr. 30, 2021.
83. S. Penckofer, et al. "Vitamin D and depression: Where is all the sunshine?" *Issues in Mental Health Nursing,* vol. 31,6 (2010): 385–93. doi:10.3109/01612840903437657.
84. E. Golovina, et al. "GWAS SNPs impact shared regulatory pathways amongst multimorbid psychiatric disorders and cognitive functioning," *Frontiers in Psychiatry,* Oct. 23 2020 https://doi.org/10.3389/fpsyt.2020.560751.
85. Lin Chin-Chuen and Tiao-Lai Huang. "Brain-derived neurotrophic factor and mental disorders," *Biomedical Journal,* vol. 43, no. 2, 2020, pp. 134–42, ISSN 2319-4170, https://doi.org/10.1016/j.bj.2020.01.001.
86. A. M. Dlugos, et al. "Negative emotionality: Monoamine oxidase B gene variants modulate personality traits in healthy humans," *Journal of Neural Transmission* (Vienna, 1996), vol. 116,10 (2009): 1323–34. doi:10.1007/s00702-009-0281-2.
87. "Genes may make some people more prone to anxiety," *American Psychological Association,* Public Affairs Monograph (Washington DC, 2008), https://www.apa.org/news/press/releases/2008/08/genes-anxiety. Retrieved Apr. 30, 2021.

88. B. M. Heiny, et al. (1998). "Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract," *Anticancer Res.*, 18:583–86.
89. S. de Groot, et al. "Effects of short-term fasting on cancer treatment," *Journal of Experimental and Clinical Cancer Research: CR,* vol. 38,1 209. May. 22, 2019, doi:10.1186/s13046-019-1189–9.
90. S. K. Denduluri, et al. "Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance," *Genes and Diseases,* vol. 2, no. 1, 2015, pp. 13–25, ISSN 2352-3042. https://doi.org/10.1016/j.gendis.2014.10.004.
91. Ibid.
92. C. C. Onunogbo, et al. 2013. "Effect of mistletoe (*Viscum album*) extract on the blood glucose, liver enzymes and electrolyte balance in alloxan induced diabetic rats," *American Journal of Biochemistry and Molecular Biology,* 3: 143–50. https://scialert.net/fulltext/?doi=ajbmb.2013.143.150.
93. A. E. Eno, et al. "Stimulation of insulin secretion by Viscum album (mistletoe) leaf extract in streptozotocin-induced diabetic rats," *Afr. Journal Med. Med. Sci,* Jun. 2008;37(2):141–47. PMID: 18939397.

Chapter 6

1. R. Steiner, lecture of Oct. 27, 1922 p.m. in *Physiology and Healing: Treatment, Therapy, and Hygiene* (CW 314), Op. cit.
2. M. Protsiv, et al. "Decreasing human body temperature in the United States since the Industrial Revolution," *eLife,* 2020; 9: e49555. Published online Jan 7, 2020.
3. Z. Obermeyer, et al. "Individual differences in normal body temperature: longitudinal big data analysis of patient records," *BMJ (Clinical research ed.),* vol. 359 j5468. Dec. 13, 2017, doi:10.1136/bmj.j5468.
4. D. B. Boivin, et al. "Circadian sex differences in sleep and alertness," *Proceedings of the National Academy of Sciences,* Sep 2016, 201524484. doi: 10.1073/pnas.1524484113.
5. D. B. Boivin, et al. "Diurnal and circadian variation of sleep and alertness in men vs. naturally cycling women," *Proceedings of the National Academy of Sciences of the United States of America,* vol. 113,39 (2016): 10980–5. doi:10.1073/pnas.1524484113.
6. J. E. Sullivan, et al. "Fever and antipyretic use in children," *Pediatrics,* vol. 127,3 (2011): 580–87. doi:10.1542/peds.2010-3852.
7. Ibid.
8. Author Note: Information about these kinds of lemon treatments for fever can be found at https://www.pflege-vademecum.de/anwendungen_bei_fieber.php.
9. H. J. Hamre, et al. "Antibiotic use in children with acute respiratory or ear infections: Prospective observational comparison of anthroposophic and conventional treatment under routine primary care conditions," *Evidence-based Complementary and Alternative Medicine: eCAM,* vol. 2014 (2014): 243801. doi:10.1155/2014/243801.

10. T. von Schoen-Angerer, et al. "Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis," *Complementary Therapies in Medicine,* vol. 40, Oct. 2018, pp. 191–94.
11. T. Ostermann, et al. "Effects of rhythmic embrocation therapy with solum oil in chronic pain patients: A prospective observational study," *The Clinical Journal of Pain,* vol. 24,3 (2008): 237–43. doi:10.1097/AJP.0b013e31816021 43.
12. P. Selg, *Helene von Grunelius und Rudolf Steiners Kurse für junge Mediziner: Eine biographische Studie* [Helene von Grunelius and Rudolf Steiner's course for young doctors: A biographical study], Dornach, Switzerland: Verlag am Goetheanum, 2003.
13. L. E. Williams and J. A Bargh. "Experiencing physical warmth promotes interpersonal warmth." *Science* (New York), vol. 322,5901 (2008): 606-7. OR Oct. 24, 2008: 322(5901):606–07 doi:10.1126/science.1162548.
14. L. K. Curran, et al. "Behaviors associated with fever in children with autism spectrum disorders," *Pediatrics,* vol. 120,6 (2007): e1386-92. doi:10.1542/peds.2007-0360.

CHAPTER 7

1. L. LeShan, *Cancer as a Turning Point: A Handbook for People with Cancer, Their Families, and Health Professionals,* New York: Plume, 1994.
2. M. Girke, *Internal Medicine: Foundations and therapeutic concepts of Anthroposophic Medicine* (Berlin: Salumed-Verlag, 2016), chap. 2; 1.0-1.5.
3. Ibid., chap. 14; 2.3.
4. Ibid., chap. 1.6 – 1.7.
5. Ibid., chap. 2.0-2.2.3.
6. Ibid., chap. 1.
7. M. Moreno-Smith, et al. "Impact of stress on cancer metastasis," *Future Oncology* (London), vol. 6,12 (2010): 1863–81. doi:10.2217/fon.10.142.
8. K. Esposito, et al. "Metabolic syndrome and risk of cancer: A systematic review and meta-analysis," *Diabetes Care,* vol. 35,11 (2012): 2402–11. doi:10.2337/dc12-0336. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476894/#:~:text=Findings%20from%20this%20meta%2Danalysis,by%20accompanying%20obesity%20of%20hyperglycemia.
9. S. P. Megdal, et al. "Night work and breast cancer risk: A systematic review and meta-analysis," *European Journal of Cancer* (Oxford, UK, 1990) vol. 41,13 (2005): 2023–32. doi:10.1016/j.ejca.2005.05.010.
10. E. McNeely, et al. "The self-reported health of U.S. flight attendants compared to the general population," *Environ. Health,* 13, 13 (2014). https://doi.org/10.1186/1476-069X-13-13.
11. M. Girke, *Internal Medicine,* Op. cit., chap. 14.2 –14.4.
12. C. Tautz: *Kinderkrankheiten als Weg zur Immunkompetenz* [Childhood illnesses as a path toward immune competence] (Berlin: Der Merkurstab, 2002), pp. 24-29.
13. M. Girke. *Internal Medicine,* Op. cit., chap. 14.2.4.4.

14. S. C. Segerstrom and G. E Miller. "Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry," *Psychological Bulletin,* vol. 130,4 (2004): 601–30. doi:10.1037/0033-2909.130.4.601.
15. M. P. da Silveira, et al. "Physical exercise as a tool to help the immune system against covid-19: An integrative review of the current literature," *Clinical and Experimental Medicine,* vol. 21,1 (2021): 15–28. doi:10.1007/s10238-020-00650-3.
16. J. R. Infante, et al. "Levels of immune cells in transcendental meditation practitioners," *International Journal of Yoga,* vol. 7,2 (2014): 147–51. doi:10.4103/0973-6131.133899.
17. V. J. Felitti, et al. "Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The adverse childhood experiences (ACE) study," *American Journal of Preventive Medicine,* vol. 14,4 (1998): 245–58. doi:10.1016/s0749-3797(98)00017-8.
18. S. A. Font and K. Maguire-Jack, "Pathways from childhood abuse and other adversities to adult health risks: The role of adult socioeconomic conditions," *Child Abuse and Neglect,* 51, no. 2 (2016): 390–99.
19. H. Alcalá, et al. "Gender differences in the association between adverse childhood experiences and cancer," *Women's Health Issues,* 27, no. 6 (2017): 625–31.
20. B. von Laue. *Natur- und Geistesgeschichtliche Aspekte der Tumorentwicklung* [Natural and spiritual developmental aspects of tumor development] (Berlin: Der Merkurstab, 1999). p. 145.
21. R. Steiner, *Physiology and Healing: Treatment, Therapy, and Hygiene,* lect. 1, Dec. 7, 1920. Op. cit.
23. L. LeShan, *Cancer as a Turning Point,* Op cit.
24. X. Yuan, et al. "Night-shift work increases the risks of multiple primary cancers in women: A systematic review and meta-analysis of 61 articles," Op. cit.
25. E. Pukkala, et al. "Incidence of cancer among Finnish airline cabin attendants, 1967–92," Op cit.
26. S. P. Tsai, et al. (Apr. 2004). "Mortality patterns among residents in Louisiana's industrial corridor, USA, 1970–99," *Occup. Environ. Med.,* 61 (4): 295–304.
27. Centers for Disease Control. (2002). Cancer Prevention and Control "Cancer Burden Data Fact Sheets, Louisiana," Atlanta, GA.
28. A. D. Blodgett. "An analysis of pollution and community advocacy in 'Cancer Alley': Setting an example for the environmental justice movement in St James Parish, Louisiana," *Local Environment,* 11(6) (2007), 647–61, DOI: 10.1080/13549830600853700.
29. K. Turner, *Radical Remission: Surviving Cancer against All Odds,* San Francisco: HarperOne, 2015.
30. C. Tautz. *Kinderkrankheiten als Weg zur Immunkompetenz* [Childhood illnesses as a path toward immune competence] (Berlin: Der Merkurstab, 2002), pp. 24–29.
31. M. Orange, "Mistletoe fever with subcutaneously injected mistletoe," *Der Merkurstab*; 5/2017; pp 377–83.

32. D. Furman, et al. "Chronic inflammation in the etiology of disease across the life span," *Nature Medicine,* vol. 25,12 (2019): 1822-1832. doi:10.1038/s41591-019-0675-0.
33. M. Girke. *Internal Medicine,* Op. cit., chap. 5; 1.0-2.3.
34. K. H. Allin, et al. "Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer," *Critical Reviews in Clinical Laboratory Sciences,* vol. 48,4 (2011): 155-70. doi:10.3109/10408363.2011.599831.
35. AUTHOR NOTE: Such observations have been noticed by a group for rhythmic studies at the Carl Gustav Carus Institute in Niefern-Öschelbronn, Germany. I have also noticed some preliminary animal research here: A. Karakas, et al. "Effects of European mistletoe (*Viscum album* L. subsp. *album*): Extracts on activity rhythms of the Syrian hamsters (*Mesocricetus auratus*)," *Natural Product Research,* 22:11 (2008), 990–1000, DOI: 10.1080/14786410701654776.
36. M. Orange, et al. "Durable regression of primary cutaneous b-cell lymphoma following fever-inducing mistletoe treatment: Two case reports," *Phytomedicine,* 20, nos, 3–4 (Feb. 15, 2013): 324–27.
37. J. Blume, et al. "Immune suppression and immune activation in depression," *Brain, Behavior, and Immunity,* vol. 25,2 (2011): 221–29. doi:10.1016/j.bbi.2010.10.008.
38. E. Reiche et al. "Stress, depression, the immune system, and cancer," *The Lancet. Oncology,* vol. 5,10 (2004): 617–25. doi:10.1016/S1470-2045(04)01597-9.
39. S. C. Segerstrom and G. E Miller. "Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry," Op cit.
40. V. J. Felitti, et al. "Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ACE) study," Op. cit.
41. S. A. Font and K. Maguire-Jack, "Pathways from childhood abuse and other adversities to adult health risks: The role of adult socioeconomic conditions," Op. cit.
42. H. Alcalá, et al. "Gender differences in the association between adverse childhood experiences and cancer," Op. cit.
43. L. LeShan. *Cancer as a Turning Point,* Op. cit.
44. B. M. Heiny, et al (1998). "Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract," *Anticancer Res.*, 18:583–86.
45. G. S. Kienle, et al. "Intravenous mistletoe treatment in integrative cancer care: A qualitative study exploring the procedures, concepts, and observations of expert doctors," *Evidence Based Complementary Alternative Medicine* (2016):4628287. ePub Apr. 24, 2016.
46. V. Bott. *Spiritual Science and the Art of Healing: Rudolf Steiner's Anthroposophical Medicine,* New York: Healing Arts Press,1996.
47. M. Gierke. *Internal Medicine,* Op. cit., chap. 1.2.
48. M. Debus. "Mistletoe induction therapy and advanced dosing protocols," *Mistletoe and Integrative Oncology: European Research and Best Practices 2020.* Presented by the Physicians' Association for Anthroposophic